{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-045313","form_type":"8-K","ticker":null,"cik":"0001850079","company_name":"Telesis Bio Inc.","filed_at":"2024-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.813826+00:00","generated_at":"2026-06-03T19:29:51.951246+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Telesis Bio appoints Eric Esser as CEO; shifts focus to Gibson SOLA EDS and BioXp mRNA","bullets":["Eric Esser named President and CEO effective April 16, 2024, replacing founder Todd Nelson who remains on board.","Esser receives $490k base salary, 100% target bonus, 100k RSUs, and 200k stock options.","Operating expenses reduced from $14.3M (Q4 2022) to $10.8M (Q4 2023), extending cash runway.","Commercial focus on Gibson SOLA enzymatic DNA synthesis; secured co-development deal with automation provider.","BioXp focused on mRNA synthesis; distribution agreement with Avantor expands channel reach."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-045313","json":"https://secwatch.observer/filing/0000950170-24-045313.json","markdown":"https://secwatch.observer/filing/0000950170-24-045313.md","text":"https://secwatch.observer/filing/0000950170-24-045313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024045313/0000950170-24-045313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024045313/tbio-20240417.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T19:29:51.951246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23ef0d9d2d","claim":"Eric Esser was appointed as President and Chief Executive Officer at Telesis Bio Inc..","evidence_excerpt":"Eric Esser, who had been serving as the Company's President and Chief Operating Officer, assumed the position of President and CEO for the Company, effective as of April 16, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024045313/0000950170-24-045313-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assumed position"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"755de09862","claim":"Todd R. Nelson changed role as Chief Executive Officer at Telesis Bio Inc..","evidence_excerpt":"Todd R. Nelson, Ph.D., Founder, Chief Executive Officer (CEO) of the Company and member of the Company’s Board of Directors (the Board), will cease serving as the Company's CEO, effective as of April 16, 2024, and will remain a member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024045313/0000950170-24-045313-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving as CEO"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d568c33283","claim":"Eric Esser was appointed as Class II Director at Telesis Bio Inc..","evidence_excerpt":"the Board approved the expansion of the Board from seven to eight members and appointed Mr. Esser to serve as a Class II director, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024045313/0000950170-24-045313-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}